Jump to main content

First Gene Therapy for Hemophilia B, CSL’s HEMGENIX®, Approved by the European Commission

Approval of HEMGENIX® underscores CSL’s promise to deliver life-changing innovations that have the potential to help patients lead full lives.

Story

Global biotechnology leader CSL today announced that the European Commission has granted conditional marketing authorization (CMA) for HEMGENIX® (etranacogene dezaparvovec).